Localized amyloidosis at the site of enfuvirtide injection

Annals of Internal Medicine

Volumn 151, Issue 7, 2009, Pages 515-516

  Morilla, Miguel Emilio ^a   Kocher, Jeffrey ^a   Harmaty, Marco ^b  

^a ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ENFUVIRTIDE;

ADD ON THERAPY; ADULT; AMYLOIDOSIS; ANAMNESIS; CASE REPORT; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INJECTION SITE ERYTHEMA; LEG PAIN; LETTER; MALE; MALE HOMOSEXUAL; NEUROPATHY; PRIORITY JOURNAL; SKIN CYST; SUBCUTANEOUS NODULE; TREATMENT DURATION; TREATMENT WITHDRAWAL; VIRUS LOAD; VIRUS RESISTANCE;

EID: 70349734668     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-151-7-200910060-00017     Document Type: Letter

References (14)

1. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al; TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185 [PMID: 12637625] (Pubitemid 36618128)
2. Church JA, Hughes M, Chen J, Palumbo P, Mofenson LM, Delora P, et al; Pediatric AIDS Clinical Trials Group P1005 Study Team. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2004;23:713-718 [PMID: 15295220]
3. Myers SA, Selim AA, McDaniel MA, Hall R, Zhang Y, Bartlett JA, et al. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. Antivir Ther. 2006;11:935-939 [PMID: 17302257] (Pubitemid 44736186)
4. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, et al; TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195 [PMID: 12773645] (Pubitemid 36618129)
5. Ball RA, Kinchelow T; ISR Substudy Group. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol. 2003;49:826-831 [PMID: 14576660]
6. Maggi P, Ladisa N, Cinori E, Altobella A, Pastore G, Filotico R. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother. 2004;53:678-681 [PMID: 14985276] (Pubitemid 38499790)
7. Steciuk A, Dompmartin A, Troussard X, Verneuil L, Macro M, Comoz F, et al. Cutaneous amyloidosis and possible association with systemic amyloidosis. Int J Dermatol. 2002;41:127-32; discussion 133-134 [PMID: 12010335] (Pubitemid 34601104)
8. Nguyen TU, Oghalai JS, McGregor DK, Janssen NM, Huston DP. Subcutaneous nodular amyloidosis: a case report and review of the literature. Hum Pathol. 2001;32:346-348 [PMID: 11274647]
9. Love WE, Miedler JD, Smith MK, Mostow EN, Cooper KD, Gilliam AC. The spectrum of primary cutaneous nodular amyloidosis: Two illustrative cases [Letter]. J Am Acad Dermatol. 2008;58:S33-5. [PMID: 18191697]
10. Störkel S, Schneider HM, Müntefering H, Kashiwagi S. Iatrogenic, insulin-dependent, local amyloidosis. Lab Invest. 1983;48:108-111 [PMID: 6337294]
11. Swift B. Examination of insulin injection sites: an unexpected finding of localized amyloidosis [Letter]. Diabet Med. 2002;19:881-882 [PMID: 12358880] (Pubitemid 35177192)
12. Dische FE, Wernstedt C, Westermark GT, Westermark P, Pepys MB, Rennie JA, et al. Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia. 1988;31:158-161 [PMID: 3286343] (Pubitemid 18104125)
13. Ciin LC, Barker D, Tymms DJ. Unexpected finding of amyloidosis at the site of insulin injection. Pract Diab Int. 2005;22:118. (Pubitemid 40823755)
14. Wei BP, Somers GR, Castles L. Dystrophic calcification and amyloidosis in old subcutaneous injection sites. ANZ J Surg. 2003;73:556-558 [PMID: 12864841] (Pubitemid 37000033)